Atlas Molecular Pharma, approval for the treatment of Congenital Erythropoietic Porphyria

ATlas-molecular-Pharma
Share on linkedin
Share on twitter
Share on email

This post is also available in: Spanish

Atlas Molecular Pharma, a private company founded in 2015 in Derio (Spain) as a spin-off from the Centre for Co-operative Research in Biosciences (CIC bioGUNE), receives approval by the European Commission of Ciclopirox as an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria.

“The favourable report from the European Medicines Agency and the approval of Ciclopirox as OMP by the European Commission are very important steps in the development of Ciclopirox for the treatment of Congenital Erythropoietic Porphyria. “ATLAS will continue with plans for the development of Ciclopirox. The new OMP status will facilitate the process and ultimately contribute to our goal of delivering Ciclopirox to patients suffering from Congenital Erythropoietic Porphyria at the earliest time possible”, said Dr. Emilio Díez, CEO and CSO of Atlas.

ABG IP is proud to collaborate with Atlas Molecular Pharma and CIC bioGUNE in the IP protection of this ciclopirox medicine.

For more information, see the press release issued by Atlas Molecular Pharma.

ABG IP
ABG is a leading European IP firm. ABG’s more than 60 professionals combine experience, outstanding technical knowledge and deep legal expertise to be at the forefront of IP law.
ABG IP on EmailABG IP on Linkedin

Share this post with interested parties

Share on linkedin
Share on twitter

Subscribe to our Newsletter

Next Events

No event found!

Relevant news